PDCD1 and rheumatoid arthritis: The molecular parallelism between the natural history of RA disease progression and Nivolumab or anti-PD-1 antagonist gene signature suggests that the PD-1 co-inhibitory pathway dysregulation may result in breakdown of immune tolerance in autoimmunity development in both cancer and RA patients.